Key result
Cardiology society statements fail to improve sex-specific outcome reporting in major cardiovascular trials.
Observational
Answers are grounded in this paper and cite their sources.
In the past decade, the leading international cardiology societies have released statements that emphasize the importance of sex-specific reporting of the findings of clinical trials in cardiovascular research. To find out whether this has led to improvement, we compared sex-specific reporting of efficacy and safety outcomes for trials of cardiovascular drug interventions presented at the major clinical trials sessions of the European Society of Cardiology (ESC), American Heart Association (AHA) and the American College of Cardiology (ACC) before and after publication of these statements. We found that sex-specific efficacy and safety outcomes of the most influential cardiovascular intervention trials are still not systematically presented.
No takes yet. Share an insight, caveat, or question.
Schreuder et al. (2020) conducted an observational in Cardiovascular disease. Cardiology society statements on sex-specific reporting vs. Trials presented before publication of society statements was evaluated on Sex-specific reporting of efficacy and safety outcomes. Cardiology society statements did not lead to systematic presentation of sex-specific efficacy and safety outcomes in major cardiovascular drug intervention trials.
Synapse has enriched 10 related papers. Consider them for comparative context: